Bristol Myers Squibb Co (BMY) Stock Price & Analysis

Bristol Myers Squibb Co (BMY) rose 0.00% to USD 62.09 as of July 25, 2026 at 01:12 UTC, according to Nexqual real-time market data.

BMY last closed at USD 62.09; the session ranged USD 61.62–62.82 on volume of 11,975,333 shares. Market capitalization is —, with a 52-week range of USD 42.52–62.89 (NYQ). Source: Nexqual, July 25, 2026 at 01:12 UTC.

Key Statistics (as of July 25, 2026 at 01:12 UTC)

Technical Analysis (BMY)

Nexqual's technical model rates BMY "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 01:12 UTC.

Leadership (BMY)

Bristol Myers Squibb Co is led by Christopher S. Boerner (age 54), CEO & Chairman, per Nexqual as of July 25, 2026 at 01:12 UTC.

Major Backers & Investors (BMY)

Notable institutional backers of Bristol Myers Squibb Co include JPMorgan, Charles Schwab Investment Management, Inc., Charles Schwab, according to Nexqual as of July 25, 2026 at 01:12 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 01:12 UTC.

From Bristol Myers Squibb Co's Latest SEC 10-K Filing (filed 2026-02-11)

Key Strengths & Strategy (as disclosed to the SEC)

• Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
• The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
• Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM.
• The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:12 UTC. This page is informational and not investment advice.